BiomX Inc. announced on September 18, 2024, that it would present further data from its Phase 1b/2a study of BX004 for the treatment of cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference.
Study data from Part 1 showed that subjects receiving the BX004-A cocktail achieved a greater reduction in P. aeruginosa colony-forming units (CFU)/g of sputum at day 15 versus baseline, compared to placebo. In Part 2, 14% of subjects receiving BX004-A had a negative PsA sputum culture on day 10, while 0% of the placebo group did.
Additionally, lung function, measured by forced expiratory volume in 1 second (FEV1), increased by 5.66% in a subgroup of patients receiving the cocktail, compared to a decrease of 3.23% in the placebo group. These results were observed in a subgroup on continuous inhaled antibiotics, on elexacaftor/tezacaftor/ivacaftor, and with lower lung function (FEV1 <70%).
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.